HIV Infection Clinical Trial
Official title:
A Randomized Trial of Interleukin-2 With or Without a Tumor Necrosis Factor Antagonist in Patients With HIV-1 Infection
Patients enrolled in NIH protocol 95-I-0133 at the Clinical Center may participate in an
extension phase of this study in which the drug prednisone will be eliminated from the
treatment regimen. Prednisone is associated with avascular necrosis, a condition that has
been found in a number of patients in this study. Also, certain patients in this protocol
may receive future interleukin-2 treatment cycles at home. Home administration of IL-2
injections involves less frequent data and safety monitoring and no medical evaluations at
the Clinical Center except at the beginning of each cycle.
To be eligible for home administration of IL-2, patients must:
- Be enrolled in a current NIAID protocol for IL-2 therapy and have received at least 1
year of treatment on the protocol, with at least two well-tolerated outpatient cycles
at a stable dose.
- Have a history of tolerable side effects while receiving IL-2 without frequent medical
interventions, intravenous fluid replacement or dose reductions.
- Not have had any significant clinical or laboratory abnormalities during days 0 to 5 of
the last two outpatient cycles.
- Have a strong relationship with a private physician or health-care provider who has
been involved in the patient's care and is willing to help supervise the patient's care
during each home IL-2 cycle.
- Live in a home with easy telephone access and have proved reliable in responding to
telephone calls from clinic staff.
- Give the clinic staff contact information for a close friend or relative who will agree
to serve as a caregiver during each home cycle, providing the patient non-medical
assistance and checking on his or her condition daily.
- Have reasonable access to emergency medical services and a nearby medical facility.
- Have proved reliable and consistent in using sterile technique, reconstituting IL-2
vials and administering subcutaneous IL-2 injections.
- Be receiving outpatient IL-2 injections cycles at least once every 6 months as part of
their normal protocol participation.
- Have access to a home weight scale and be able to weigh themselves each day for safety
monitoring.
Participants will receive IL-2 cycles on the same schedule they followed in their original
protocol participation. They will be seen at the Clinical Center at regularly scheduled
follow-up visits between cycles and for a medical evaluation and blood drawing before the
start of each cycle to determine the safety of administering the cycle. During the home
cycle, the patient's case manager or other team member will place monitoring telephone calls
on days 2 and 4 of the cycle and again a week later. The timing and number of these calls
may change depending on the findings of ongoing assessments of their usefulness. Patients
will be required to notify the study team promptly of any complications or other problems
that develop with therapy.
In the initial phase of this study, HIV-infected patients with CD4 counts between 200 and
500 were randomized to receive either IL-2 alone by continuous IV infusion for 5 days every
8 weeks, IL-2 plus anti-TNF antibody, or IL-2 plus thalidomide. The primary endpoints of
this study are safety and tolerability of the IL-2/TNF inhibitor combination. Secondary
endpoints will include changes in CD4 counts, frequency and severity of IL-2 related side
effects, changes in serum TNF levels, and plasma viral load changes. The study period is one
year, with an optional extension period to follow. Enrollment was for up to forty-five
IL-2-naive patients.
In the amended phase of this study, up to 60 patients with HIV infection and CD4 counts
equal to or greater than 350 will be studied to determine the ability of prednisone to
ameliorate IL-2 related toxicity. Patients will be randomized to one of four groups: IL-2
alone; IL-2 plus prednisone; prednisone alone; no treatment. All four groups will be treated
with a combination regimen of antiretrovirals to include at least one protease inhibitor.
IL-2 will be dosed SQ at a starting dosage of 7.5 mlU bid x 5 days every 8 weeks, and
prednisone (or placebo) will be dosed at 0.5 mg/kg/day during IL-2 cycles. Primary endpoints
are frequency of IL-2 associated fatigue and fever, CD4 count changes, and viral load
changes. Secondary endpoints include frequency of other IL-2 side effects, concomitant
medication use, steroid associated side effects, cytokine changes during IL-2, and IL-2
total exposure in the IL-2 plus steroid vs. IL-2 plus placebo arms. The study period is one
year with an optional extension period to follow.
;
Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02135419 -
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
|
Phase 3 | |
Active, not recruiting |
NCT02663856 -
My Smart Age With HIV: Smartphone Self-assessment of Frailty
|
||
Completed |
NCT02663869 -
Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles
|
||
Completed |
NCT02921516 -
Growing Up: Intervening With HIV-Positive Adolescents in Resource-Poor Settings
|
N/A | |
Completed |
NCT02846402 -
Impact of HIV Self-testing Among Female Sex Workers in Kampala, Uganda
|
N/A | |
Terminated |
NCT02743598 -
Liraglutide for HIV-associated Neurocognitive Disorder
|
Phase 4 | |
Completed |
NCT02659306 -
Metformin Immunotherapy in HIV Infection
|
Phase 1 | |
Completed |
NCT02564341 -
Targeting Effective Analgesia in Clinics for HIV - Intervention
|
N/A | |
Active, not recruiting |
NCT02302950 -
A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas
|
N/A | |
Completed |
NCT02269605 -
Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment
|
Phase 1 | |
Terminated |
NCT01902186 -
Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir
|
Phase 4 | |
Terminated |
NCT02109224 -
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
|
Phase 1 | |
Completed |
NCT01852942 -
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
|
Phase 2 | |
Completed |
NCT01830595 -
Lactoferrin Treatment in HIV Patients
|
Phase 2 | |
Completed |
NCT02525146 -
Birmingham Access to Care Study
|
N/A | |
Completed |
NCT01946217 -
Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials
|
N/A | |
Completed |
NCT02118168 -
Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002
|
N/A | |
Completed |
NCT02527135 -
Text Messaging to Improve HIV Testing Among Young Women in Kenya
|
N/A | |
Active, not recruiting |
NCT02602418 -
Neural Correlates of Working Memory Training for HIV Patients
|
N/A | |
Completed |
NCT01702974 -
Immune Reconstitution in HIV Disease (IREHIV)
|
Phase 2 |